论文部分内容阅读
目的研究探讨不同肠内营养制剂对急性重症脑卒中后营养代谢支持的效果。方法 50例急性重症脑卒中患者作为研究对象,按照随机对照原则分为观察组与对照组,各25例。其中观察组以瑞高作为肠内营养制剂,对照组则以瑞素作为肠内营养制剂。两组患者均于发病早期给予肠内营养,且营养支持的时间≥2周。对两组患者进行营养支持前及营养支持后第1周、第2周的血清白蛋白(ALB)、血清总蛋白(TP)、空腹血糖(Glu)及血红蛋白(Hb)水平进行监测,同时注意观察患者的不良反应。结果营养支持第1周,两组患者的ALB、TP、Hb均较治疗前显著下降,差异具有统计学意义(P<0.05),其中观察组患者的Glu明显升高,对比营养支持前差异具有统计学意义(P<0.05),对照组治疗1周后与营养支持前比较差异无统计学意义(P>0.05)。营养支持第2周检测得出,观察组的Hb与ALB明显高于对照组,差异均具有统计学意义(P<0.05)。两组患者的胃肠道不良反应情况均较低,组间比较差异无统计学意义(P>0.05)。结论以瑞高为代表的高蛋白营养剂可显著改善患者的营养状况,且耐受性较好,具有较好的临床应用前景。
Objective To study the effect of different enteral nutrition on nutrition and metabolic support after acute severe stroke. Methods Fifty patients with acute severe stroke were divided into the observation group and the control group according to the principle of randomized control, with 25 cases in each. The observation group to Swiss high as enteral nutrition preparations, while the control group is used as Reutin as enteral nutrition preparations. Two groups of patients were given enteral nutrition early in the disease, and nutritional support for more than two weeks. The serum albumin (ALB), serum total protein (TP), fasting blood glucose (Glu) and hemoglobin (Hb) level were monitored before nutrition support and after nutrition support in the two groups at the same time. Observe the patient’s adverse reactions. Results In the first week of nutritional support, ALB, TP and Hb in both groups were significantly lower than those before treatment, with statistical significance (P <0.05). Glu in the observation group was significantly higher than that before treatment (P <0.05). There was no significant difference in the control group after one week of treatment and before nutritional support (P> 0.05). The results of the second week of nutritional support showed that Hb and ALB in the observation group were significantly higher than those in the control group, with statistical significance (P <0.05). Gastrointestinal adverse reactions were lower in both groups, with no significant difference between the two groups (P> 0.05). Conclusion High protein nutrition represented by Swissgard can significantly improve the nutritional status of patients with good tolerance and good clinical application prospects.